The United States Supreme Court last week rejected British Petroleum's (BP) plea to halt payments under the settlement agreement. BP had appealed District Court Judge Barbier's findings to the Fifth Circuit Court of Appeals. The Fifth Circuit issued a ruling rejecting BP's argument that the settlement agreement was unfair and would dole out billions to businesses whose claims were unrelated to the oil spill disaster. BP then appealed the Fifth Circuit's ruling to the Supreme Court, who refused to hear the matter.
This is a huge victory for all of those businesses that were affected by the tragic environmental disaster. BP has tried to do everything it could do to get out of the deal that their lawyers and hired CPA firms reviewed and advised to sign.
Thursday, June 19, 2014
Tuesday, June 10, 2014
Low T Cases Consolidated Into MDL
The U.S. Judicial Panel on Multidistrict Litigation (JPML)
has ordered all product liability lawsuits filed in U.S. District Courts
nationwide involving injuries associated with the use of any testosterone
replacement therapy (TRT) to be centralized before one judge in the Northern
District of Illinois as part of an MDL, or multidistrict litigation.
Following oral arguments late last month in Dallas, Texas,
the JPML issued an order on June 6, which transfers cases involving any “Low T”
drugs to U.S. District Judge Matthew F. Kennelly for coordinated handling
during pretrial proceedings.
Testosterone is a hormone that promotes the growth of the
male reproductive system, contributes to proper sexual function, boosts libido,
prevents loss of scalp hair and can reduce the accumulation of abdominal fat.Treatment is
often prescribed to men in order to counteract the age-related decline in the
hormone. It helps improve sex drive, bone density and muscle mass. But the
benefits and risks of the long-term use of testosterone therapy are not well
known. Testosterone therapy is most often administered as a gel, patch or injection.
There are approximately 45 filed Low T lawsuits in Federal
districts throughout the country. Major side effects claimed in these lawsuits
include stroke, heart attack or even
death. Use of the medication has been linked to certain other risks,
including heart problems, sleep apnea, high red blood cell production, skin
reactions, breast enlargement and lower sperm production.
The following products treat low testosterone:
- Androgel
- Androderm
- Axirom
- Bio-T-Gel
- Delatestryl
- Depo-Testosterone
- Fortesta
- Striant
- Testim
- Testopel
The U.S. Food and Drug Administration (FDA) is investigating
the risk of stroke, heart attack, and death in men taking FDA-approved
testosterone products. It has been monitoring this risk and decided to reassess
this safety issue based on the recent publication of two separate studies that
each suggested an increased risk of cardiovascular events among groups of men
prescribed testosterone therapy.
Pittman, Dutton & Hellums, P.C., is currently
investigating Low T Therapy claims. If you or a loved one were prescribed
testosterone therapy and were injured as a result, please contact Booth Samuels
at 1-866-515-8880 or by email at booths@pittmandutton.com.
Monday, June 9, 2014
O'Bannon Trial Started Today
The Ed O'Bannon class action lawsuit against the NCAA
started this morning in Oakland, California. Mr. O'Bannon took the stand
earlier today.
The trial was originally slated to be a jury trial, but the
Plaintiffs withdrew their request and Judge Wilken is now presiding over a
bench trial. The Plaintiffs also withdrew their individual damages
claims.
The case was also paired with a similar class action suit
brought by Sam Keller. That case was bifurcated and was slated to go to trial
in February 2015, but in an announcement made in Court this morning before
trial, that case has settled. The NCAA settled that lawsuit for a reported $20
million and will go towards student athletes who appeared in EA Sports video
games. This on top of the previous settlement with EA for $40 million.
For more on the trial, click on the below links:
Subscribe to:
Posts (Atom)